Voting Results of Cosmo's 2026 AGM
Dublin, Ireland--(Newsfile Corp. - April 10, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting (AGM). A total of 10,354,065 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 59.02% of the total outstanding ordinary shares in the share capital of Cosmo as of the record
Healthcare and Hospitals, Health
2026-04-10 9:16 AM EDT | Cosmo Pharmaceuticals N.V.
Theralase(R) Closes $CAN 2.66 Million Financing
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering ("Offering
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-04-10 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Robert Bitterman, Chief Executive Officer and Chairman of the Board, will present at the Centri Capital Conference on Tuesday, April 14, 2026, at Nasdaq Marketsite in New York City. The present
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-09 7:00 AM EDT | Phio Pharmaceuticals Corp.
MyndTec Inc. Announces Inability to Secure Financing, Cessation of Operations and Evaluation of Strategic Alternatives Including Insolvency Proceedings
Mississauga, Ontario--(Newsfile Corp. - April 8, 2026) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company") announces that it has been unable to secure the additional financing required to continue operations. As previously disclosed, the Company's operations during 2024 and 2025 were substantially funded by its principal shareholder, Jim Anderson, through his participation in successive private placement offerings. Mr. Anderson has confirmed that he will not be mak
Technology, Healthcare and Hospitals, Health
2026-04-08 12:17 PM EDT | MyndTec Inc.
Trenchant Technologies Capital Corp. Announces Unwinding of Previous Limitless Quantum Acquisition
Vancouver, British Columbia--(Newsfile Corp. - April 8, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTCQB: AITTF) ("Trenchant" or the "Company") announces that it has entered into a share exchange agreement dated March 18, 2026 and fully executed on April 5, 2026, (the "Share Exchange Agreement") providing for the unwinding of the Company's previously announced acquisition of Limitless Quantum Computing Solutions Inc. ("Limitless Quantum") (collective
Technology, Banking / Financial Services, Biotechnology, Healthcare and Hospitals
2026-04-08 11:46 AM EDT | Trenchant Technologies Capital Corp.
Adia Nutrition Strikes Major Partnership with Leading Atlanta Clinic to Launch Groundbreaking Autism Clinical Study
Winter Park, Florida--(Newsfile Corp. - April 8, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today announced a strategic partnership with a prominent clinic in Atlanta, Georgia. Adia Labs will serve as the exclusive supplier of regenerative products for the clinic's new Autism Spectrum Disorder (ASD) clinical study. This partnership is a key part of Adia Nutrition's 2026 plan to build solid scientific evidence for regenerative therapies that have the potenti
Healthcare and Hospitals, Health
2026-04-08 8:30 AM EDT | Adia Nutrition Inc.
The Obesity Medicine Association Hosts Obesity Medicine 2026: The Heart of Obesity Care
Denver, Colorado--(Newsfile Corp. - April 8, 2026) - The Obesity Medicine Association (OMA), the nation's oldest medical society dedicated exclusively to obesity treatment, will host its annual conference, Obesity Medicine 2026: The Heart of Obesity Care, April 10-12 in San Diego, California. Bringing together more than 1,500 clinicians, researchers, and industry leaders, the conference highlights the latest science, clinical strategies, and innovations shaping the future of obesity med
Healthcare and Hospitals, Health
2026-04-08 8:00 AM EDT | Obesity Medicine Association
LevelJump Announces Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - April 7, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), a leading provider of teleradiology and diagnostic imaging services, today announced that it intends to complete a non-brokered private placement (the "Offering") of up to 15,000,000 common shares (the "Shares") of the Company at a price of $0.05 per Share, for gross proceeds of up to $750,000. Completion of the Offering is subject to the approval of the TSX Ventu
Healthcare and Hospitals, Health
2026-04-07 6:18 PM EDT | LevelJump Healthcare Corp.
Canadian Ophthalmologists Highlight Seasonal Environmental Risks to Eye Health
Ottawa, Ontario--(Newsfile Corp. - April 7, 2026) - Ophthalmologists across Canada are observing the impact of seasonal environmental exposures — including ultraviolet (UV) radiation, wildfire smoke, and airborne allergens — on patients' ocular health and visual comfort. As these factors intensify during the spring and summer months, the Canadian Ophthalmological Society (COS) is underscoring the importance of awareness and preventive care to reduce both immediate irritation and l
Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-07 7:30 AM EDT | Canadian Ophthalmological Society (COS)
Les ophtalmologistes canadiens mettent en garde contre les risques environnementaux saisonniers pour la santé oculaire
Ottawa, Ontario--(Newsfile Corp. - 7 avril 2026) - Partout au pays, les ophtalmologistes constatent les effets des expositions environnementales saisonnières, notamment le rayonnement ultraviolet (UV), la fumée des feux de forêt et les allergènes en suspension dans l'air - sur la santé oculaire et le confort visuel des patients. À mesure que ces facteurs s'intensifient au printemps et à l'été, la Société canadienne d'ophtalmologie (SCO) s
Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-07 7:30 AM EDT | Canadian Ophthalmological Society (COS)
TelyRx Holdings Inc. to Commence Trading on the Toronto Stock Exchange Effective April 7, 2026
Clearwater, Florida--(Newsfile Corp. - April 7, 2026) - TelyRx Holdings Inc. (TSX: TELY) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced that its subordinate voting shares will commence trading on the Toronto Stock Exchange ("TSX") under the ticker symbol "TELY" effective Tuesday, April 7, 2026. This milestone follows the completion of its go-public transaction pursuant to the combination with Apolo V Acquisiti
Healthcare and Hospitals, Health
2026-04-07 7:00 AM EDT | TelyRx
Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets
Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of methadone hydrochloride 5 mg and 10 mg tablets. Methadone tablets are indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative o
Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-02 8:00 AM EDT | Elite Pharmaceuticals, Inc.
Resverlogix Corp. Announces Issuance of MCTO by ASC
Calgary, Alberta--(Newsfile Corp. - April 2, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the issuance of a management cease trade order ("MCTO") by the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), following an application made by the Company, and first announced on March 17, 2026 (the "Original Announcement"). The MCTO relates to Resverlogix's default on the prescribed deadl
Technology, Biotechnology, Healthcare and Hospitals
2026-04-02 7:15 AM EDT | Resverlogix Corp.
Adia Nutrition, Inc. Reports Strong Revenue Growth in 2025 Annual Report, Highlighting Transition to Regenerative Medicine and Full SEC Reporting Status
Winter Park, Florida--(Newsfile Corp. - April 1, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced key highlights from its Form 10-K annual report for the year ended December 31, 2025. The filing marks a pivotal year of operational expansion following the company's successful transition from a dormant shell to an active player in the high-growth regenerative healthcare sector. In 2025, Adi
Healthcare and Hospitals, Health
2026-04-01 10:07 AM EDT | Adia Nutrition Inc.
Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - April 1, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, announced that the first three patients implanted in its pivotal clinical trial for the fully implanted Acclaim® cochlear implant have successfully completed their 12-month endpoint visit, marking a key milestone in the study's pr
Biotechnology, Healthcare and Hospitals
2026-04-01 8:00 AM EDT | Envoy Medical, Inc.
Scryb Reports 2026 AGM Results and Welcomes Veteran Capital Markets and Finance Directors
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company") is pleased to announce the results of its Annual General Meeting of shareholders (the "AGM") held on March 31, 2026. All resolutions presented at the AGM received overwhelming shareholder support, with more than 99% of votes cast in favour. This strong approval reflects shareholder confidence in the Company's management team, leadership, refreshed strategy, and long-
Biotechnology, Healthcare and Hospitals, Health
2026-04-01 7:06 AM EDT | NorthPalm Capital Corp.
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
Calgary, Alberta--(Newsfile Corp. - March 31, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") is providing an update on the management cease trade order ("MCTO") application it made to the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"). The application remains under review, and no decision has yet been made by the ASC. The Company announced on March 17, 2026 (the "Original Announcement") that
Technology, Biotechnology, Healthcare and Hospitals
2026-03-31 7:09 PM EDT | Resverlogix Corp.
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to provide a corporate update from Dr. Carolyn Myers, the Company's President and CEO. Dear FendX Shareholders, Over the past several months, FendX has achieved meaningful pro
Technology, Healthcare and Hospitals, Health
2026-03-31 7:00 AM EDT | FendX Technologies Inc.
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply for future clinical trials. The company will manufacture Phio's lead compo
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-30 7:00 AM EDT | Phio Pharmaceuticals Corp.
The Future of Skin Aging May Be Found in The Kitchen: 2026 American Academy of Dermatology Annual Meeting to Highlight Latest Advancements in Skin, Hair, and Nails
Denver, Colorado--(Newsfile Corp. - March 27, 2026) - As interest grows in how lifestyle factors can influence people's appearance, dermatologists are taking a closer look at how diet may affect the internal and structural changes that contribute to the appearance of aged skin. Emerging research on the role of nutrition in skin aging is one of the timely and impactful topics that will be discussed at the 2026 American Academy of Dermatology (AAD) Annual Meeting, held March 27-31 in Denver, Co
Healthcare and Hospitals, Health
2026-03-27 9:00 AM EDT | American Academy of Dermatology